SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001829126-23-006440
Filing Date
2023-10-04
Accepted
2023-10-04 17:30:18
Documents
3
Group Members
SEOW GIM SHEN

Document Format Files

Seq Description Document Type Size
1 SC 13D titanpharma_sc13d.htm SC 13D 92199
2 EXHIBIT 4 titanpharma_ex99-4.htm EX-99.4 36468
3 EXHIBIT 5 titanpharma_ex99-5.htm EX-99.5 7218
  Complete submission text file 0001829126-23-006440.txt   137464
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Subject) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-46083 | Film No.: 231309020
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address NO. 4, FRANKY BUILDING PROVIDENCE INDUSTRIAL ESTATE MAHE T2 00000
Business Address NO. 4, FRANKY BUILDING PROVIDENCE INDUSTRIAL ESTATE MAHE T2 00000 6012 484 4444
Sire Group Ltd. (Filed by) CIK: 0001995392 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NY
Type: SC 13D